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Pathogenic fungi are associated with diseases ranging from simple dermatosis to life-threatening in-
fections, particularly in immunocompromised patients. During the past two decades, resistance to
established antifungal drugs has increased dramatically and has made it crucial to identify novel anti-
microbial compounds.
Here, we selected 12 new compounds of 2-amino-4H-benzochromene-3-carbonitrile drivetives (C1-
C12) for synthesis by using nano-TiCl4.SiO2 as efﬁcient and green catalyst, then nine of synthetic com-
pounds were evaluated against different species of fungi, positive gram and negative gram of bacteria.
Standard and clinical strains of antibiotics sensitive and resistant fungi and bacteria were cultured in
appropriate media. Biological activity of the 2-amino-4H-benzochromene-3-carbonitrile derivatives
against fungi and bacteries were estimated by the broth micro-dilution method as recommended by
clinical and laboratory standard institute (CLSI). In addition minimal fangicidal and bactericial con-
centeration of the compounds were also determined.
Considering our results showed that compound 2-amino-4-(4-methyl benzoate)-4H-benzo[f]chro-
men-3-carbonitrile (C9) had the most antifungal activity against Aspergillus clavatus, Candida glabarata,
Candida dubliniensis, Candida albicans and Candida tropicalis at concentrations ranging from 8 to128 mg/
mL. Also compounds 2-amino-4-(3,4-dimethoxyphenyl)-4H-benzo[f]chromen-3-carbonitrile (C4) and 2-
amino-4-(4-isopropylphenyl)-4H-benzo[f]chromen-3-carbonitrile (C3) had signiﬁcant inhibitory activ-
ities against Epidermophyton ﬂoccosum following 2-amino-4-(4-methylbenzoate)-4H-benzo[f]chromen-
3-carbonitrile (C9), respectively.
Docking simulation was performed to insert compounds C3, C4 and C9 in to CYP51 active site to
determine the probable binding model.
© 2016 Elsevier B.V. All rights reserved.1. Introduction
During the past two decades, resistance to established antimi-
crobial drugs has increased dramatically and it is serious public
health problem in a wide range of infectious disease [1e3]. These
resistant strains cause failure in treatment and enhance mortalityani).risks, and sometimes contribute to complications. Unlike antibac-
terial antibiotics, the variety of antifungal drugs is restricted due to
the similarity of structure andmetabolism of eukaryotic fungal cells
to those of mammalian cells. Hence, the discovery of antifungal
agents that possess selective toxicity against the eukaryotic fungal
cell remains an important scientiﬁc challenge. Considering the
limited diversity of antifungal agents and recent resistance of fungi
to the known antifungal drugs, the development of new bioactive
compounds effective against resistant strains is highly needed. In
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available for medical use, the antimicrobial resistance created
substantial medical need for new classes of antimicrobial agents.
Design and synthesis of newer antimicrobials will always remain an
area of immense signiﬁcance [4,5]. Among the important phar-
macophores responsible, the chromene moiety is an important
structural shape of many synthetic compounds of biological and
pharmaceutical interest such as cytotoxicity [6], antioxidant [7],
antiplasmodial [8], antimalarial [9], antirhinovirus [10], antifungal
[11] and antibacterial [12].
A particularly interesting group of chromenes are 2-amino-4H-
benzo[f]chromenes which are generally prepared by reaction of
malononitrile, aldehydes and naphthols in one-pot procedure. This
multicomponent reaction has been catalyzed with K2CO3 [13], Mg/
Alhydrotalcite [14], nano-sized magnesium oxide [15], Preyssler
heteropolyacid [16], basic alumina [17], potassium phosphate
tribasic trihydrate [18], cetyltrimethylammonium bromide (CTABr)
[19], sodium carbonate [20], DBU [21], 3-butyl-1-
methylimidazolium hexaﬂuorophosphate, 1-methyl imidazoliu-
miodide [mim]Cl [22], Na2CO3 [23] and tetrabutylammonium-
bromide (TBABr) [24].
However, each method has certain restrictions with regards to
scope and reaction conditions; for example, longer reaction times,
puriﬁcation problems and harsh reaction conditions. To avoid these
limitations, our studies towards the development of more capable
methods accompanied with higher yields for the synthesis of 2-
amino-4H-benzochromene-3-carbonitrile in the presence of
nano-TiCl4.SiO2. We previously described the design and synthesis
of some organic reactions in princess of solid acid catalysts as a
green, cheap and efﬁcient technique [25e30].
Also, some of the synthesized compounds were evaluated for
their antifungal and antibacterial activity.
The antibacterial activities of the above compounds were
compared to Ampicillin as positive control and the antifungal ac-
tivities of them were evaluated to Fluconazole.
2. Materials and methods
2.1. Chemistry
The chemicals were purchased from Merck and used without
any additional puriﬁcation. The products were characterized by FT-
IR (ATR), 1H NMR, and a comparison of their physical properties
with those reported in the literature. FT-IR (ATR) spectra were ac-
quired on a Bruker, Eqinox 55 spectrometer. A Bruker (DRX-400
Avance) nmr was used to record the 1H NMR spectra. Spectro-
photometer (UV/Vis biotek model UVIKONXL), Melting points were
determined with a Thermo Scientiﬁc Electrothermal digital appa-
ratus (Thermo Fisher Scientiﬁc Inc.), Gass Chromatography Mass
Spectrometery (Agilent 7000 Series Triple Quad -MS, Made in USA).
2.2. Docking studies
Molecular vina docking studies were performed using PYRX
software [Wolf LK, Chem Eng News. 2009 87: 31], the complex of
enzymeMycobacterium tuberculosis-CYP51 with Fluconazole (PDB
ID: 1EA1) was obtained from Protein Data Bank (http://www.rcsb.
org), Water molecules and cognate ligand were removed from the
receptor. The chemical structures were drawn into computer using
HyperChem software (Version 7, Hypercube Inc), then the semi-
empirical AM1 method was used for geometry optimization and
saved in pdb ﬁle format. Binding mode ﬁgures were generated with
PYMOL.3.3. General procedure for synthesis of 2-amino-4H-benzo-
chromene-3-carbonitrile.
A mixture of aldehyde (1 mmol), malononitrile (1mmole),naphthol (1 mmol) and nano-TiCl4.SiO2 (0.1 g) was stirred at 90 C
under solventefree conditions. The progress of the reaction was
monitored by thin layer chromatography (TLC). After completion of
the reaction, the reaction mixture was dissolved to CHCl3 and
ﬁltered. The catalyst residue was washed with acetone and reused.
The product was triturated with 2 mL of cooled ethanol to give the
solid product. The spectroscopy of the pure products has been
shown in Table 1.
2.3. Determination of antifungal activities
2.3.1. Microorganisms
The antifungal activities of the synthetic compounds against
some American Type Culture Collection (ATCC) strains of fungi,
including Aspergillus ﬂavus (ATCC 64025), Aspergillus fumigatus
(ATCC 14110), Aspergillus clavatus, Candida albicans (ATCC 1912), C.
albicans (ATCC 1905), C. albicans (SUCC 2303), C. albicans (SUCC 625),
Candida glabarata (ATCC 2192), C. glabarata (ATCC 863), C. glabarata
(ATCC 2175), C. glabarata (ATCC 2175), Candida dubliniensis (ATCC
8501), C. dubliniensis (ATCC 7988), Candida tropicalis (SUCC 194), C.
tropicalis (SUCC 611), C. tropicalis (ATCC 750), Cryptococcus neo-
formance (ATCC 9011), as well as two clinical isolates of yeasts
identiﬁed by PCR-RFLP were determined. Moreover, the inhibitory
activities of the mentioned compounds against dermatophytes
(Trichophyton rubrum, Microsporum canis and Epidermophyton ﬂo-
cossum) which were identiﬁed by morphological and physiological
tests were also examined in this study. The susceptibility of all
clinical isolates of fungi against selected antibiotics was examined
by microdilution and disk diffusion methods [31,32]
2.3.1.1. Determination of minimum inhibitory concentration.
MICs were determined using the broth microdilution method rec-
ommended by the CLSI with somemodiﬁcations [31,32]. Brieﬂy, for
determination of antimicrobial activities against fungi, serial di-
lutions of the synthetic compounds (1e1024 mg/mL) were prepared
in 96-well microtiter plates using RPMI-1640 media (Sigma, St.
Louis, MO, USA) buffered with MOPS (Sigma). Stock inoculums
were prepared by suspending three colonies of the examined yeast
in 5 mL sterile 0.85% NaCl, and adjusting the turbidity of the in-
oculums to 0.5 McFarland standards at 530 nm wavelengths (this
yields stock suspension of 1e5  106 cells/mL). For moulds
(Aspergillus spp. and dermatophytes), conidia were recovered from
the 7-day old cultures grown on potato dextrose agar by a wetting
loop with tween-20. The collected conidia were transferred in
sterile saline and their turbidity was adjusted to OD ¼ 0.09e0.11
that yields 0.4e5  106 conidia/mL. Working suspension was
prepared by making a 1/50 and 1/1000 dilution with RPMI of the
stock suspension for moulds and yeasts, respectively. Working in-
oculums (0.1 mL) were added to the microtiter plates, which were
incubated in a humid atmosphere at 30 C for 24e48 h. Uninocu-
latedmedium (200 mL) was included as a sterility control (blank). In
addition, growth controls (medium with inoculums but without
antibiotics or the synthetic compounds) were also included. The
growth in each well was compared with that of the growth in the
control well.
3. Results and discussion
3.1. Chemistry
Our investigation is based on the development of heterogeneous
catalyst for reducing risks to human and the environment. For
ﬁnding the best reaction conditions, the reaction of benzaldehyde,
malononitrile and 2-naphthol was examined under various states.
According to the obtained results, the best result was obtained in
Table 1
Spectral data of 2-amino-4H-benzochromene-3-carbonitrile compounds.
Compound Mp (_C) Spectral data
Found
reported[ref]
C1 273-274 273-275
[20]
FT-IR (neat, ATR)¼ 3429, 3336 (stretch, NH2), 2181 (stretch, CN), 1638 (bending, NH2), 1408, 1588 (stretch, C]C), 1261, 1024 (stretch, C-O)
cm1, 1H NMR (400 MHz, CDCl3), d (ppm) ¼ 7.8 (m, 2H7,10), 7.7 (d, J ¼ 7.2 Hz, 1H6), 7.4 (m, 2H8,9), 7.29 (m, 1H40), 7.26 (m, 2H30 ,50), 7.20 (d,
J ¼ 7.2 Hz, 3H20 , 60 , 5), 5.26 (s, 1H1), 4.57 (s, 2H, NH2), MS: (m/z, %), 297 (Mþ, 10), 221 (100).
C2 217-219 - FT-IR (neat ATR) ¼ 3463, 3353 (stretch, NH2), 2189 (stretch, CN), 1656 (bending, NH2), 1588, 1410 (stretch, C]C),1526, 1348 (stretch, N]
O), 1216, 1028 (stretch, C-O) cm1, 1H NMR (400 MHz, CDCl3), d (ppm) ¼ 8.1 (s br, 1H20), 8.08 (d, J¼ 8 Hz, 1H40), 7.99 (d, J¼ 8.8 Hz, 1H6), 7.9
(m, 2H7,10), 7.6 (t, J¼ 8, 1H50), 7.4 (d, J¼ 7.6 Hz, 1H60), 7.4 (m, 2H8,9), 7.38 (d, J¼ 9.2, 1H5), 6.42 (s, 2H, NH2), 5.6 (s, 1H1), MS: (m/z, %), 343 (Mþ,
15), 221 (100).
C3 217-219 - FT-IR (neat ATR) ¼ 3423, 3335 (stretch, NH2), 2190 (stretch, CN), 1647 (bending, NH2), 1589, 1412 (stretch, C]C), 1233, 1038 (stretch, C-O)
cm1, 1H NMR (400MHz, CDCl3), d (ppm)¼ 7.81 (d, J¼ 8.4 Hz, 2H7,10), 7.72 (m, 1H6), 7.4 (m, 2H8,9), 7.26 (m, 1H5), 7 (s br, 4H20 ,3’.50 ,60), 5.23 (s,
1H1), 4.55 (s, 2H, NH2), 2.83 (sept. J ¼ 7.2 Hz, 1Hisopropyl), 1.18 (d, J ¼ 7 Hz, 6Hisopropyl), MS: (m/z, %), 337 (30), 91 (100).
C4 190-192 - FT-IR (neat ATR) ¼ 3428, 3333 (stretch, NH2), 2185 (stretch, CN), 1648 (bending, NH2), 1589, 1403 (stretch, C]C), 1260, 1231, 1134, 1017
(stretch, C-O) cm1, 1H NMR (400 MHz, CDCl3), d (ppm) ¼ 7.8 (d, J ¼ 8.4, 2H7,10), 7.7 (m, 1H6), 7.4 (m, 2H8,9), 7.25 (d, J ¼ 9.6 Hz,1H5), 6.7 (d,
J¼ 6.8, 2H50 ,60), 6.66 (d, J¼ 8.4 Hz, 1H20), 5.21 (s, 1H1), 4.6 (s, 2H, NH2), 3.80 (s, 3H methoxy), 3.78 (s, 3Hmethoxy), MS: (m/z, %), 358 (Mþ, 25), 221
(100).
C5 258-263 - FT-IR (Neat) ¼ 3401(stretch, NH2), 2194 (stretch, CN), 1710 (stretch, C]O), 1664 (bending, NH2), 1606, 1411(stretch, C]C), 1280, 1106
(stretch, C-O of ester), 1189, 1029 (stretch, C-O) cm1, 1H NMR (400MHz, CDCl3), d (ppm)¼ 7.9 (d, J¼ 8.4 Hz, 2H30 ,50), 7.8 (m, 2H7,10), 7.6 (m,
1H6), 7.4 (m, 2H8,9), 7.27 (t, J ¼ 2.8 Hz, 3H20 ,60 ,5), 5.3 (s, 1H4), 4.65 (s, 2H, NH2), 3.87 (s, 3Hmethy), MS: (m/z, %), 357 (Mþ), 314 (60), 221 (100).
C6 238-240 232-234
[21]
FT-IR (neat ATR) ¼ 3461, 3322 (stretch, NH2), 2200 (stretch, CN), 1658 (bending, NH2), 1587, 1404 (stretch, C]C), 1260, 1045 (stretch, C-O)
cm1, 1H NMR (400MHz, CDCl3), d (ppm)¼ 7.83 (m, 2H7,10), 7.6 (d, J¼ 7.2, 1H6), 7.4 (m, 3H8,9,5), 7.25 (m, 1H30), 7.04 (d, J¼ 8.4, 1H50), 6.8 (d,
J ¼ 8.4, 1H60), 5.84 (s, 1H1), 4.65 (s, 2H, NH2), MS: (m/z, %), 366 (Mþ, 5), 221 (100).
C7 271-273 259-261
[20]
FT-IR (neat ATR)¼ 3458, 3349 (stretch, NH2), 2178 (stretch, CN), 1654 (bending, NH2), 1589, 1409 (stretch, C]C), 1219, 1040 (stretch, C-O),
798 (bending C-H) cm1, 1H NMR (400 MHz, CDCl3), d (ppm)¼ 7.8 (m, 2H7,10), 7.67 (d, J¼ 8 Hz, 1H6), 7.4 (m, 3H8,9,30), 7.25 (m, 1H40), 7.1 (m,
2H50 ,60), 6.9 (d, J ¼ 7.2 Hz, 1H5), 5.9 (s, 1H1), 4.62 (s, 2H, NH2), MS: (m/z, %), 332 (Mþ, 15), 221 (100).
C8 256-257 - FT-IR (neat ATR)¼ 3434, 3328 (stretch, NH2), 2185 (stretch, CN), 1649 (bending, NH2), 1585, 1408 (stretch, C]C), 1227, 1024 (stretch, C-O),
798, 724 (bending C-H) cm1, 1H NMR (400MHz, CDCl3), d (ppm)¼ 7.9 (m, 3H7,10,6), 7.4 (m, 2H8,9), 7.3 (d, J¼ 8.8 Hz, 1H5), 6.94 (s, 1H20), 6.69
(d, J ¼ 8.4 Hz, 1H60), 6.6 (d, J ¼ 8 Hz, 1H50), 6.14 (s, 2H, NH2), 5.24 (s, 1H1), MS: (m/z, %), 326 (15), 221 (100).
C9 232-235 - FT-IR (neat ATR) ¼ 3379, 3313 (stretch, NH2), 2195 (stretch, CN), 1707 (stretch, C]O), 1650 (bending, NH2), 1590, 1404 (stretch, C]C),
1287, 1187 (stretch, C-O of ester), 1233, 1022 (stretch, C-O), 726 (bending C-H) cm1,1H NMR (400MHz, CDCl3), d (ppm)¼ 7.9 (d, J¼ 8.4 Hz,
2H30 ,50), 7.8 (m, 2H7,10), 7.6 (m, 1H6), 7.4 (m, 2H8,9), 7.27 (t, J ¼ 2.8 Hz, 3H20 ,60 ,5), 5.3 (s, 1H1), 4.65 (s, 2H, NH2), 3.87 (s, 3Hmethy), MS: (m/z, %),
357 (Mþ), 314 (60), 221 (100).
C10 163-164 - FT-IR (neat ATR) ¼ 3392, 3346 (stretch, NH2), 2221(stretch, CN), 1657 bending, NH2), 1597, 1481 (stretch, C]C), 694 (bending C-H) cm1,
1H NMR (400 MHz, CDCl3), d (ppm) ¼ 7.3 (m, 9H6,7,8,9,10,30 ,40 ,50 ,60), 7.1 (d, J ¼ 6.8 Hz, 1H20), 7.0 (d, J ¼ 8 Hz 1H5), 5.0 (s, 1H1), 3.8 (s, 2H, NH2),
3.05 (t, J ¼ 7.6 Hz, 2Hmethylene), 2.7 (t, J ¼ 8 Hz, 2Hmethylene), MS: (m/z, %), 326 (Mþ, 15), 221 (100).
C11 211-214 - FT-IR (Neat ATR) ¼ 3344 (stretch, NH2), 2194 (stretch, CN), 1667 1647 (bending, NH2), 1573, 1398 (stretch, C]C), 1103 (stretch, C-O), 797
(bending C-H) cm1, 1H NMR (400 MHz, CDCl3), d (ppm) ¼ 8.18 (d, J ¼ 8 Hz, 1H7), 7.79 (d, J ¼ 7.6 Hz, 1H10), 7.5 (m, 3H6,8,9), 7.15(s br,
4H20 ,3’.50 ,60), 7.06 (d, J ¼ 8.4, 1H5), 4.85 (s, 1H4), 4.72 (s, 2H, NH2), 2.87(sept. J ¼ 6.8 Hz, 1Hisopropyl), 1.2 (d, J ¼ 6.8 Hz, 6Hisopropyl), MS: (m/z, %),
337 (30), 91 (100).
C12 222-224 - FT-IR (Neat ATR) ¼ 3343, 3331(stretch, NH2), 2195(stretch, CN), 1667(bending, NH2), 1601, 1404 (stretch, C]C), 1272, 1037 (stretch, C-O),
804(bending C-H) cm1, 1H NMR (400 MHz, CDCl3), d (ppm) ¼ 7.9 (m, 3H7,10,6), 7.4 (m, 2H8,9), 7.3 (d, J ¼ 8.8 Hz, 1H5), 6.94 (s, 1H20), 6.69 (d,
J ¼ 8.4 Hz, 1H60), 6.6 (d, J ¼ 8 Hz, 1H50), 6.14 (s, 2H, NH2), 5.24 (s, 1H4), MS: (m/z, %), 326 (15), 221 (100).
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tions (Table 2, Entry 8).
Then, scope of synthesis of 2-amino-4H-benzochromene-3-
carbonitrile using a wide range of aromatic aldehydes was inves-
tigated and it can be seen in Table 3 and Fig. 1. Clearly, the reactivity
of aldehyde is the key factor for this one-pot protocol. Electron
deﬁcient aromatic aldehydes produced higher yields of production
in a shorter time in comparison to the aldehayes that are rich in
electrons.
Meanwhile, both aldehyde groups of terphthaldialdehyde reac-
ted tomalononitrile and 2-naphthol. The productionwas 4, 40-(1, 4-
phenylene)bis(2-amino-4H-benzo[f]chromene-3-carbonitrile)
with 92% yield after 100 min at 90 C (Scheme 1).
Trioxan as a source of formaldehyde reacted to 2-naphthol and
malononitrile. It produced 2-amino-4H, 4H mixing at 90 C
(Scheme 2).In reaction of 3-phenyl propionaldehyde as an aliphatic
aldehyde with malononitrile and 2-naphthol, corresponding
chromene product was obtained in 80% yield after 100 min at
90 C. In this protocol, 4-(N,N-dimethylamino) benzaldehyde as
an aldehyde with electron releasing group only reacted to
malononitrile and produced benzylidinemalononitrile with 85%
yield after 120 min mixing at 90 C. Ketones such as, acetophe-
none did not produced any chromene derivatives in condensa-
tion with malononitrile and 2-naphthol. It only produced
methylbenzylidinemalononitrile with 88% yield after 150 min at
90 C.
3.2. Antifungal activities of the synthetic compounds
In this study, nine compounds (C1-C9) evaluated against fungi
(Table 4). On the other hands, compounds C1, C2, C5, C6, C7 and C8
Table 2
Synthesis of 2-amino-4-phenyl-4H-benzo[f]chromen-3-carbonitrilein various conditions.a
Entry Catalyst Mol% (g) ArOH Condition Solvent Product [Yield(%)][ref]
1 Na2CO3 10 a-naphthol Grinding e 4 [92%] [23]
2 Na2CO3 10 b-naphthol 125

C e 5 [100%] [20]
3 TBABr (0.8) a-naphthol MW H2O 4 [94%] [24]
4 K2CO3 10 b-naphthol MW e 4[92%] [13]
5 CTABr (0.01 mL) b-naphthol Reﬂux 110 C H2O 5 [80%] [19]
6 Mg/Al (HT) 50 a-naphthol MW e 4 [84%] [14]
7 g-alumina.H2O e a-naphthol Reﬂux H2O 4 [96%] [17]
8 Nano-TiCl4.SiO2 0.1 b-naphthol 90

C e 5 [98%]-
9 Nano-TiCl4.SiO2 0.15 b-naphthol 90

C e 5 [98%]-
10 Nano-TiCl4.SiO2 0.05 b-naphthol 90

C e 5 [85%]-
11 Nano-TiCl4.SiO2 0.1 b-naphthol 80

C e 5 [90%]-
12 Nano-TiCl4.SiO2 0.1 b-naphthol 110

C e 5 [98%]-
13 Nano-TiCl4.SiO2 0.1 b-naphthol Reﬂux Water 5 [70%]-
14 Nano-TiCl4.SiO2 0.1 b-naphthol Reﬂux EtOH 5 [78%]-
15 Nano-TiCl4.SiO2 0.1 b-naphthol Reﬂux EtOH: H2O 5 [85%]-
16 Nano-TiCl4.SiO2 0.1 b-naphthol Reﬂux EtOAc 5 [80%]-
17 Nano-TiCl4.SiO2 0.1 b-naphthol Reﬂux n-Hexane 5 [80%]-
18 Nano-TiCl4.SiO2 0.1 b-naphthol Sonication EtOH: H2O 5 [75%]-
a The molar ratio of benzaldehyde: naphthol: and malonitrile is 1: 1: 1.
Table 3
Preparation of 2-amino-4H-benzochromene-3-carbonitrile in the presence of nano-TiCl4.SiO2a.
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Fig. 1. Synthesis of 2-amino-4H-benzochromene-3-carbonitrile.
OH O
H
X
CNCN
nano-TiCl4.SiO2
90 C
O O
NC NH2CNH2N
solvent-free
Scheme 1. Synthesis of 4,40-(1,4-phenylene)bis(2-amino-4H-benzo[f]chromene-3-carbonitrile).
B.F. Mirjalili et al. / Journal of Molecular Structure 1116 (2016) 102e108106showed no antifungal activities against examined Candida, Asper-
gillus strains and dermatophytes. Compound C9 exhibited fungicidal
activity against A. clavatus, C. glabarata, C. dubliniensis, C. albicans,
and C. tropicalis. In comparing MIC values of the synthetic com-
pounds, C4 exhibited strong inhibitory activities against Epi-
dermophyton ﬂoccosum followed in activity by C3 and C9,
respectively.
In this class, replacement of hydrogen with methoxy residue in
para and meta-positions of phenyl ring of C4 increased its anti-
fungal activity against E. ﬂoccosum (at concentrations ranging from
1 to 32 mg/mL) compared to C1 (Table 4).
In addition, isopropyl substitution at para position of the phenyl
ring of C3 improved of its antifungal activity against the tested
E. ﬂoccosum at concentrations ranging from 2 to 8 mg/mL compared
to C1 (Table 3). Replacement of methyl ester at para position of
phenyl ring provided C9would result in signiﬁcant enhancement ofOH
CNCN
O O
O
nano-T
90
solve
Scheme 2. Synthesis of 2-amino-4H,4Hthe inhibitory activity against E. ﬂoccosum at concentrations
ranging from 8 to 16 mg/mL. Also this compound showed good
fungistatic and fungicidal activity against some species of Candida
at concentrations ranging from 16 to 128 mg/mL (Table 4). This
might be probably due to higher solubility of C9 than the other
compounds in aquatic media.
Also, in this survey, showed that E. ﬂoccosum was the most
sensitive of the studied dermatophytes, that good inhibited by C4,
C3 and C9 compared to T. rubrum and M. canis.
None of the synthetic compounds had any effect on negative
gram and positive gram of microorganisms except C1 that it had
inhibitory effects on S. aureus microorganism.
In comparison of the antifungal and antibacterial activities of
the synthetic compounds based on variation of substitutions on
ortho, meta and para position of phenyl ring, we found that the
base compound C1 exhibited a better antibacterial activity againstO
NC NH2
(E)
H
H
iCl4.SiO2
 C
nt-free
-benzo[f]chromen-3-carbonitrile.
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B.F. Mirjalili et al. / Journal of Molecular Structure 1116 (2016) 102e108 107the tested S. aureus (positive garam microorganism) than the other
compounds. We ﬁnd Compound C9 exhibited fungicidal activity
against A. clavatus, C. glabarata, C. dubliniensis, C. albicans, and
C. tropicalis. In comparing MIC values of the synthetic compounds,
C4 exhibited strong inhibitory activities against E. ﬂoccosum fol-
lowed in activity by C3 and C9, respectively.3.3. Docking studies
The rasemate compounds were tested but docking studies of
binding mode of R and S isomer of compounds C3, C4 and C9 were
performed by PYRX to achieve better understanding on the
mechanism, potency and guide additional structureeactivity re-
lationships (SAR). According to the related literature, there are no
any experimental structural information available for the active
site of C. albicans enzyme so the most close homology X-ray
crystallographic structure of the Mycobacterium tuberculosis
enzyme CYP51 (PDB ID:1EA1) were used [33,34]. Interactions of
ﬂuconazole in active site of CYP51 for validation and comparison
were depicted in Fig. 2 (a). The R isomers have no effective
interaction so there are comparisons between isomer S of com-
pounds C3, C4 and C9 and binding model of ﬂuconazole. Fig. 2 (b,
c, and d) indicated the polar interaction with Arg 96, His 259 and
Thr 260 into the binding pocket that accommodates well to
pharmacophore residues. In summery these H-bond and hydro-
phobic interaction might be favor to the anti fungal activity. It
seems that suitable substitute on para and meta site of compounds
C3, C4 and C9 orientated toward the front of the pocket of heme
iron of CYP51, These interactions are analogous to interactions
typically seen between the triazole ring of ﬂuconazole and heme
iron of CYP51.
We have demonstrated a simple method for the synthesis of 2-
amino-4H-benzochromene-3-carbonitrile by nano-TiCl4.SiO2 as
efﬁcient catalyst under solvent-free condition. The antibacterial
and antifungal activities of nine synthetic compounds were
investigated.
It is evident that synthesized compounds, C3, C4 and C9
exhibited strong inhibitory activities against E. ﬂoccosum and
thereby, these compounds can constituting promising antifungal
both individually and in combined therapy.
A computer model of the interaction of compound C3, C4 and C9
with theMycobacterium tuberculosis enzyme CYP51 binding pocket
was proposed. The model involved a favorable polar interaction
that accommodated in complete pharmacophoric equivalency to
the known anti-fungal activity binding mode.4. Conclusion
We have demonstrated a simple method for the synthesis of 2-
amino-4H-benzochromene-3-carbonitrile by nano-TiCl4.SiO2 as
efﬁcient catalyst under solvent-free condition. The antibacterial
and antifungal activities of nine synthetic compounds were
investigated.
It is evident that synthesized compounds, C3, C4 and C9
exhibited strong inhibitory activities against E. ﬂoccosum, these
compounds can constituting promising antifungal both individu-
ally and in combined therapy.
A computer model of the interaction of compound C3, C4 and C9
with theMycobacterium tuberculosis enzyme CYP51 binding pocket
was proposed. The model involved a favorable polar interaction
that accommodated in complete pharmacophoric equivalency to
the known anti-fungal activity binding mode.
Fig. 2. (a). Molecular docking modeling perpendicular orientation of ﬂuconazole to the heme iron of CYP51, (b) Orientation compound C3, (c) Orientation compound C4 and (d)
Orientation compound C9 in active site of CYP51. Note: For clarity, only interacting residues in 12 Å were displayed.
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